Shaomeng Wang
Shaomeng Wang is the medicinal chemist behind some of the first clinical MDM2 inhibitors and PROTAC degraders.
Designed MDM2 inhibitors, BET and AR degraders, and the first STAT3 degrader to enter clinical trials; founder of several oncology biotechs.
| Title | Journal | Year |
|---|---|---|
| A selective small-molecule STAT3 degrader achieves complete tumor regression in vivo | Cancer Cell | 2019 |
Pages like this
not linked directly; found by shared links- IdeaDegrade the damaged p53 protein rather than trying to repair it
Shares PROTACs & molecular glues (targeted protein degradation), TP53.
- IdeaDestroy the truncated androgen receptor that hormone drugs cannot touch
Shares Androgen receptor, PROTACs & molecular glues (targeted protein degradation).
- Key paperThe first PROTAC: a chimeric molecule that tags a protein for destruction
Shares Androgen receptor, PROTACs & molecular glues (targeted protein degradation).
- IdeaAn open degrader consortium against every undruggable driver transcription factor
Shares PROTACs & molecular glues (targeted protein degradation), TP53.
- CompanyMonte Rosa Therapeutics
Shares Androgen receptor, PROTACs & molecular glues (targeted protein degradation).
- TargetMDM2
Shares PROTACs & molecular glues (targeted protein degradation), TP53.
- IdeaAn open-science consortium on the undruggable drivers, open until a candidate
Shares PROTACs & molecular glues (targeted protein degradation), TP53.
- PathwayTranscriptional machinery & addiction
Shares Androgen receptor, PROTACs & molecular glues (targeted protein degradation).